Literature DB >> 18295601

Cardiac release of urocortin precedes the occurrence of irreversible myocardial damage in the rat heart exposed to ischemia/reperfusion injury.

Richard A Knight1, Carol Chen-Scarabelli, Zhaokan Yuan, Roy B McCauley, J Di Rezze, Gabriele M Scarabelli, Paul A Townsend, David Latchman, Louis Saravolatz, Giuseppe Faggian, Alessandro Mazzucco, Hardial S Chowdrey, Anastasis Stephanou, Tiziano M Scarabelli.   

Abstract

This study evaluates whether cardiac ischemia induces release of urocortin, before and independently from myocyte cell death. Urocortin levels rose after 5-min ischemia and peaked after 10-min ischemia, when cell death was not detected. However, myocyte apoptosis and/or necrosis occurred following 20- and 30-min ischemia, which paralleled a fall in urocortin levels, suggesting that urocortin expression and release are mainly sustained by metabolically challenged, though still viable myocytes. Hence, since cardiac release of urocortin, unlike that of conventional biomarkers, occurs before and apart from cell death, urocortin levels may be clinically useful in the diagnosis of sublethal myocardial ischemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18295601     DOI: 10.1016/j.febslet.2008.02.035

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  7 in total

1.  CRF and urocortin 3 protect the heart from hypoxia/reoxygenation-induced apoptosis in zebrafish.

Authors:  Tegan A Williams; Jillian C Bergstrome; Juliana Scott; Nicholas J Bernier
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-05-24       Impact factor: 3.619

2.  A new model of congestive heart failure in rats.

Authors:  Jiqiu Chen; Elie R Chemaly; Li Fan Liang; Thomas J LaRocca; Elisa Yaniz-Galende; Roger J Hajjar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-06-17       Impact factor: 4.733

3.  Cardiac CRFR1 Expression Is Elevated in Human Heart Failure and Modulated by Genetic Variation and Alternative Splicing.

Authors:  Anna P Pilbrow; Kathy A Lewis; Marilyn H Perrin; Wendy E Sweet; Christine S Moravec; W H Wilson Tang; Mark O Huising; Richard W Troughton; Vicky A Cameron
Journal:  Endocrinology       Date:  2016-10-18       Impact factor: 4.736

4.  Enhanced IL-17 signalling following myocardial ischaemia/reperfusion injury.

Authors:  Seán P Barry; Samir Ounzain; James McCormick; Tiziano M Scarabelli; Carol Chen-Scarabelli; Louis I I Saravolatz; Giuseppe Faggian; Alessandro Mazzucco; Hisanori Suzuki; Christoph Thiemermann; Richard A Knight; David S Latchman; Anastasis Stephanou
Journal:  Int J Cardiol       Date:  2011-10-24       Impact factor: 4.164

5.  Vasoprotective effects of urocortin 1 against atherosclerosis in vitro and in vivo.

Authors:  Akinori Hasegawa; Kengo Sato; Remina Shirai; Rena Watanabe; Keigo Yamamoto; Kaho Watanabe; Kyoko Nohtomi; Tsutomu Hirano; Takuya Watanabe
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

6.  PDRPS7 protects cardiac cells from hypoxia/reoxygenation injury through inactivation of JNKs.

Authors:  Yulian Duan; Siyuan Cheng; Liang Jia; Zhao Zhang; Leilei Chen
Journal:  FEBS Open Bio       Date:  2020-03-16       Impact factor: 2.693

7.  The cardioprotective effects of urocortin are mediated via activation of the Src tyrosine kinase-STAT3 pathway.

Authors:  Carol Chen-Scarabelli; Louis Saravolatz Ii; Roy McCaukey; Gabriele Scarabelli; Justin Di Rezze; Bibhu Mohanty; Sean Barry; David Latchman; Vassilis Georgiadis; James McCormick; Louis Saravolatz; Richard Knight; Giuseppe Faggian; Jagat Narula; Anastasis Stephanou; Tiziano M Scarabelli
Journal:  JAKSTAT       Date:  2013-05-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.